MSB 2.11% 97.0¢ mesoblast limited

Cell Therapy News/Articles, page-17290

  1. 12,453 Posts.
    lightbulb Created with Sketch. 3375
    Has this been posted? From a friend of MSB...

    Re" Cleveland Clinic Crohn's trial...
    Anyway, results very good in the P1B/2A trial. Of the 23 patients, 18 received the MSCs and 5 were controls. No adverse events from the MSC treatment.

    83% of the treatment group had complete clinical and radiographic healing (15/18 patients) versus only 40% of the controls (2/5 patients).

    Disease activity index, incontinence and vanassche scores all significantly decreased in treatment patients at 6 months vs none decreased in the control group.

    Conclusion: Bone marrow-derived MSCs offer a safe and effective alternative treatment approach for severe peri*&^% fistulizing Crohn's disease.

    Early days, and a couple of P3 trials are yet to be done, but this could be another potential source of a strategic partnership .
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
0.020(2.11%)
Mkt cap ! $1.107B
Open High Low Value Volume
94.5¢ 98.0¢ 93.5¢ $3.680M 3.810M

Buyers (Bids)

No. Vol. Price($)
5 149921 96.5¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 60000 1
View Market Depth
Last trade - 16.10pm 12/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.